No, the fact that AMRN was asked to do an outcomes study means that they requested a path to FDA approval for an indication that requires CV outcomes data.
Nonetheless, as I published, I felt the odds of NCE were better than 50/50. Now not so sure. The decision certainly wasn't communicated to AMRN (or even made likely) long ago, or this meeting would have already occurred!
That is 100 percent incorrect... I have personally talked to omthera and they have to run an outcome study for there esprit trial just like Amarin has to do for anchor trial.. Both trials have same target population as well...
Hence your logic that outcome study equals nce is greatly flawed..
Market Data 
Markets 
AI
